RESUMO
PURPOSE: This study was designed to evaluate the use of a novel imaging technique, dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), for detecting mesenteric peritoneal metastases. METHODS: Thirty-four patients underwent preoperative conventional MRI, including T1, T2, diffusion-weighted (DWI), and delayed gadolinium MRI, as well as DCE MRI. DCE MRI involved imaging the peritoneal cavity every 9 s for 6 min. DCE images were processed to generate parametric maps of tumor vascularity. Two oncologic surgeons and a radiologist reviewed conventional MRI for all tumor and then later reviewed the conventional MRI plus the DCE parametric maps. Images were reviewed for tumor of the parietal peritoneum, porta hepatis, bowel serosa, upper small bowel mesentery, lower small bowel mesentery, and pelvis. Conventional MRI and DCE + MRI findings were compared to operative and histopathologic reports for tumor detection. PCI scores were calculated for surgery, MRI, and DCE. RESULTS: Upper mesenteric tumor was present in 21 patients. DCE images showed a sensitivity of 100%, specificity of 92%, and accuracy of 97% compared with conventional MRI sensitivity of 24%, specificity of 93%, and accuracy of 50% (p = 0.006). Lower mesenteric tumor was present in 22 patients. DCE images showed a sensitivity of 100%, specificity of 92%, and accuracy of 97% compared with conventional MRI sensitivity of 45%, specificity of 92%, and accuracy of 62% (p = 0.008). The mean surgical PCI for all 34 patients was 23.4 compared with MRI 20.0 (p = 0.003) and DCE MRI 24.1 (p = 0.26). The addition of the DCE images improved the accuracy of total PCI by > 10% in 16 (0.46) patients. For PCI regions 9-12, the mean surgical PCI was 6.0 compared with MRI 4.8 (p = 0.08) and DCE 6.6 (p = 0.02). The addition of DCE images improved the accuracy of the regional PCI > 10% in 15 (0.43) patients. CONCLUSIONS: DCE MRI provides a novel contrast tool that improves detection of mesenteric tumor. Depicting small-volume mesenteric tumor is better on DCE MRI compared with conventional MRI.
Assuntos
Mesentério , Neoplasias Peritoneais , Imagem de Difusão por Ressonância Magnética , Humanos , Imageamento por Ressonância Magnética , Mesentério/irrigação sanguínea , Mesentério/diagnóstico por imagem , Mesentério/patologia , Neoplasias Peritoneais/irrigação sanguínea , Neoplasias Peritoneais/diagnóstico por imagem , Neoplasias Peritoneais/patologiaRESUMO
PURPOSE: We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma. EXPERIMENTAL DESIGN: Peritoneal washings were obtained from 100 consecutive patients undergoing a second-look procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings. RESULTS: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings. CONCLUSIONS: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.
Assuntos
Líquido Ascítico/patologia , Quimioterapia Adjuvante , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Pessoa de Meia-Idade , Lavagem Peritoneal , Peritônio/metabolismo , Sensibilidade e Especificidade , Manejo de Espécimes , Telomerase/genética , Telomerase/metabolismoRESUMO
Clinical studies have demonstrated that circulating tumor cells (CTCs) are present in the blood of cancer patients with known metastatic disease across the major types of epithelial malignancies. Recent studies have shown that the concentration of CTCs in the blood is prognostic of overall survival in breast, prostate, colorectal, and non-small cell lung cancer. This study characterizes CTCs identified using the high-definition (HD)-CTC assay in an ovarian cancer patient with stage IIIC disease. We characterized the physical properties of 31 HD-CTCs and 50 normal leukocytes from a single blood draw taken just prior to the initial debulking surgery. We utilized a non-interferometric quantitative phase microscopy technique using brightfield imagery to measure cellular dry mass. Next we used a quantitative differential interference contrast microscopy technique to measure cellular volume. These techniques were combined to determine cellular dry mass density. We found that HD-CTCs were more massive than leukocytes: 33.6 ± 3.2 pg (HD-CTC) compared to 18.7 ± 0.6 pg (leukocytes), p < 0.001; had greater volumes: 518.3 ± 24.5 fL (HD-CTC) compared to 230.9 ± 78.5 fL (leukocyte), p < 0.001; and possessed a decreased dry mass density with respect to leukocytes: 0.065 ± 0.006 pg/fL (HD-CTC) compared to 0.085 ± 0.004 pg/fL (leukocyte), p < 0.006. Quantification of HD-CTC dry mass content and volume provide key insights into the fluid dynamics of cancer, and may provide the rationale for strategies to isolate, monitor or target CTCs based on their physical properties. The parameters reported here can also be incorporated into blood cell flow models to better understand metastasis.
RESUMO
PURPOSE: To compare retrospectively the use of magnetic resonance (MR) imaging, laparotomy reassessment, and serum CA-125 values in predicting the presence of residual tumor in women who have been treated for ovarian cancer. MATERIALS AND METHODS: This study was approved by the institutional review board, and informed consent was waived. The study was compliant with the Health Insurance Portability and Accountability Act. Seventy-six women (mean age, 59 years) with treated ovarian cancer underwent preoperative MR imaging of the abdomen and pelvis with intravenous gadolinium-based and intraluminal barium contrast material. MR findings were compared with surgical and histopathologic findings, serial and static serum CA-125 values, and clinical follow-up results. Tumor absence was proved with normal surgical results and by following up patients for at least 1 year, with no evidence of residual tumor at serial CA-125 analysis or subsequent laparotomy. McNemar test for correlated proportions was used for statistical analysis. RESULTS: Sixty-eight women had residual tumor proved at laparotomy and biopsy or at clinical follow-up. Eight patients had no evidence of residual tumor. Gadolinium-enhanced MR imaging depicted residual tumor in 61 patients (sensitivity, 90%; specificity, 88%; accuracy, 89%) compared with laparotomy, which demonstrated residual tumor in 60 patients (sensitivity, 88%; specificity, 100%; accuracy, 89%) and CA-125 values, which demonstrated residual tumor in 44 patients (sensitivity, 65%; specificity, 88%; accuracy, 67%) (P < .01). The positive predictive values for MR imaging, laparotomy, and serum CA-125 values were 98%, 100%, and 98%, respectively, whereas the corresponding negative predictive values were 50%, 50%, and 23%, respectively. In 14 patients, there was a discrepancy between the results of MR imaging and those of laparotomy. In seven patients, MR imaging depicted residual tumor that was not found at laparotomy but was proved at subsequent biopsy or clinical and imaging follow-up, with an increasing serum CA-125 level. In six patients, MR findings were normal, and subsequent laparotomy revealed small-volume residual tumor. Residual tumor was incorrectly predicted with MR imaging in one patient who had no surgical or clinical evidence of residual tumor for 1 year. CONCLUSION: Gadolinium-enhanced spoiled gradient-echo MR imaging depicts residual tumor in women with treated ovarian cancer, with an accuracy, positive predictive value, and negative predictive value that are comparable to those of laparotomy and superior to those of serum CA-125 values alone.